Eric Rothman's practice focuses on a wide variety of life sciences transactions, for both foreign and domestic clients, representing many of the world's most sophisticated life sciences companies. Mr. Rothman's clients range from early-stage biotechs to major international pharmaceutical companies, including businesses involved with drug development and manufacturing, biologics, biosimilars and other biotech products, generics and 505(b)(2) products, vaccines and diagnostics, and medical devices. Major clients include AstraZeneca, Novartis, Sandoz, Alcon, Pfizer, Celgene, Purdue Pharma, and Mundipharma.
Mr. Rothman has experience structuring and negotiating transactions for both branded and generic products, including research collaborations and license agreements, university licenses and sponsored research agreements, option agreements, pre-clinical research agreements, material transfer agreements, licenses and co-development collaborations, clinical research agreements, contract research organization (CRO) agreements, co-promotion/co-development alliances, marketing and distribution agreements, product acquisitions and divestitures, manufacturing and supply agreements, transition service agreements, pharmacovigilance agreements, contract sales organization (CSO) agreements, and various other corporate partnering structures.
Mr. Rothman also counsels clients on contentious transactional matters, including complex settlements of commercial and intellectual property disputes involving life sciences technology.
- Pfizer in a collaboration with Beam Therapeutics to advance novel in vivo base editing programs for rare genetic diseases of the liver, muscle and central nervous system, leveraging Beam’s proprietary in vivo delivery technologies which use messenger RNA and lipid nanoparticles to deliver base editors to target organs, with total deal value of up to $1.35 billion.
- Novartis in an option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab in development to treat non-small cell lung cancer and a wide range of solid tumors, with up to $1 billion in upfront consideration.
- Novartis in the divestiture of its regional rights to dementia treatment drug Exelon® (rivastigmine patch, capsules and solution) in Canada and Latin America to Knight Therapeutics for $168 million plus an additional milestone payment of up to $12 million upon the achievement of certain conditions.
- A biotechnology company in the acquisition of a solid tumor neoantigen T cell receptor R&D platform and clinical manufacturing facility, which will support the further development of its pipeline of novel cell therapies.
- AstraZeneca in an agreement with Samsung Biologics for a $331 million manufacturing agreement to produce bulk drug substance and drug product to support AstraZeneca's biologics therapeutics at Samsung's facility in Incheon, South Korea.
- AstraZeneca in agreements for the funding and global distribution of the University of Oxford's potential COVID-19 vaccine as well as the establishment of its global manufacturing and supply chain for the vaccine, including agreements with Catalent Biologics, Emergent BioSolutions, Oxford BioMedica, and Cobra Biologics.
- Novartis in the sale to Recordati of its endocrine products, including Signifor LAR and in-development follow-up osilodrostat (LCI699) for $390 million plus milestones.
- Pfizer in an extension to the Asia-Pacific region of their exclusive license to commercialize Basilea Pharmaceutica's CRESEMBA® (isavuconazole).
- Sandoz in a global settlement of its patent disputes with AbbVie in respect of a biosimilar version of Humira.
- Purdue Pharma on its exclusive option to acquire SpineThera, Inc., including lead asset SX600, a novel dexamethasone containing microsphere in development for epidural administration for lower back pain.
- Novartis in the sale to Mylan of its global cystic fibrosis products, including the TOBI® Podhaler and TOBI® solution, for $463 million.
- Novartis on its sale to Mylan of Novartis' cystic fibrosis products, which includes the TOBI Podhaler and TOBI solution.
- Global pharmaceutical company in connection with a US co-promotion arrangement with a pharmaceutical company having expertise in neurological conditions.
- Pfizer in an exclusive license to commercialize Basilea Pharmaceutica's CRESEMBA® (isavuconazole), an anti-fungal treatment for invasive aspergillosis and mucormycosis, in Europe (ex-Nordics).
- Global pharmaceutical company in connection with a US co-promotion arrangement with a pharmaceutical company having expertise in respiratory health.
- Pfizer in connection with the licensing and collaboration aspects of a Series A financing in NextCure, Inc., a biopharmaceutical company focused on the discovery and development of new immuno-oncology products in collaboration with Yale University.
- Early-stage medical device biotechnology company in connection with the structuring and negotiating of a university license to device-related intellectual property.
- Global generic pharmaceutical company in connection with a collaboration and license agreement with a generic pharmaceutical company in respect of a 505(b)(2) cardiovascular health product.
- Alcon in the formation of a strategic alliance with US-based PowerVision to develop fluid-based accommodating intraocular lenses (AIOL) for cataract patients.
- Purdue Pharma and Mundipharma International Corporation in connection with the acquisition from VM Pharma LLC of VM-902A, a first-in-class, allosteric selective tropomyosin receptor kinase A (TrkA) inhibitor, for the treatment of pain.
- Mundipharma Laboratories GmbH and Purdue Pharma in connection with their entry into a global multi program discovery and development collaboration with Laboratorios Esteve, S.A. for various next generation products for pain management.
"Rising Star"—United States (2020)
- JD, Fordham University School of Law, 2007
- BA, University of Pennsylvania, 2004, summa cum laude
- New York